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Abstract
Detection of large rearrangements in the
dystrophin gene in Duchenne and Becker
muscular dystrophy is possible in about
65-70% ofpatients by Southern blotting or
multiplex PCR. Subsequently, carrier de-
tection is possible by assessing the inten-
sity of relevant bands, but preferably by a
non-quantitative test method. Detection
of microlesions in Duchenne and Becker
muscular dystrophy is currently under
way. Single strand conformational analy-
sis, heteroduplex analysis, and the protein
truncation test are mostly used for this
purpose. In this paper we review the avail-
able methods for detection of large and
small mutations in patients and in carri-
ers and propose a systematic approach for
genetic analysis and genetic counselling of
DMD and BMD families, including pre-
natal and preimplantation diagnosis.
(JMed Genet 1997;34:805-812)
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Duchenne muscular dystrophy (DMD) is the
most frequent muscle disease in children. The
birth prevalence ofDMD is around 1 in 3500
live born males. The milder Becker muscular
dystrophy (BMD) has a lower birth prevalence
of around 1 in 18 500 live born males.' DMD
and BMD are allelic X linked recessive diseases
caused by mutations in the dystrophin gene in
the middle of the short arm of the X chromo-
some (Xp2 1).
Female relatives of DMD and BMD pa-
tients, including mothers, sisters, nieces, aunts,
and cousins, often request genetic counselling
and genetic testing as these diseases are incur-
able, severely disabling, and cause early death.
In the genetic analysis of the family, the first
question to be answered is how reliable the
diagnosis is in the index case. The certainty of
diagnosis in DMD or BMD can be established
by the criteria set by Jennekens et al.2
Subsequently, mutation detection enables car-
rier detection and prenatal diagnosis in the
family.3 ISeveral molecular methods for detec-
ting deletion heterozygotes are available.5
However, carrier detection may not be straight-
forward, as the normal X chromosome usually
masks a deletion on the other X. If the
mutation cannot be detected, determination of
serum creatine kinase (CK) activities in close
female relatives and linkage analysis with intra-
genic and flanking DNA markers can help to
determine carrier risks and accomplish prena-
tal diagnosis.
A World Wide Web site has been set up by
Drs J T den Dunnen and E Bakker with scien-
tific and diagnostic data on DMD and BMD,
including all detected rearrangements and
microlesions in the dystrophin gene (http://
ruly7O.MedFac.LeidenUniv.nl/-duchenne/).
In this paper, we propose a systematic
approach for genetic analysis in DMD and
BMD families requesting genetic counselling
and prenatal or preimplantation diagnosis.
Genetics
THE DYSTROPHIN GENE
Spanning 2.4 Mb in Xp2 1, the dystrophin gene
is the largest human gene known to date.6 7 It
contains 79 exons and codes for a 14 kb mRNA
transcript. The protein product, dystrophin,
has a molecular weight of 427 kDa.8 9 Normal-
ly, dystrophin is located underneath the muscle
cell membrane, but in DMD patients it is
virtually missing (<3%). BMD patients mostly
have 10-40% of normal dystrophin or make a
smaller or larger, less functional dystrophin
protein.''" In both DMD and BMD, partial
deletions and duplications cluster in two
recombination hot spots, one proximal at the 5'
end of the gene, comprising exons 2-20 (30%),
and one more distal, comprising exons 44-53
(70%).6 The site and size of these mutations
are very heterogeneous. DNA analysis enables
detection of partial deletions in about 65% of
patients with DMD/BMD6 12 and partial dupli-
cations in 5% of patients.'3 Frameshifting
mutations generally cause DMD, while in
BMD the reading frame of the gene is usually
intact. This frameshift model complies with the
phenotype in 92% of cases.'4 Detection of mic-
rolesions like point mutations is under way but
not routine yet in most laboratories.'5 16 Micro-
lesions are more difficult to find in the incom-
parably large dystrophin gene as they do not
cluster in certain regions of the gene.
MOSAICISM
Germline mosaicism in DMD was first decrib-
ed by Bakker et al. 17 Many reports have
followed since. 18-24 Subsequent brothers and
sisters of a patient with an apparent new muta-
tion have an estimated risk of 5-10% of inher-
iting the same mutation owing to germline
mosaicism. Passos-Bueno et af' found different
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Figure 1 Multiplex PCR shows deletion of exon 47 in the
DMD patient (P) and not in a normal control (C).
frequencies of mosaicism for proximal and dis-
tal deletions and duplications in the dystrophin
gene in familial and isolated cases, indicating a
difference in the aetiology of the mutations.
They observed a much higher frequency of
proximal gene rearrangements in "proven"
germline mosaics. No such differences were
found in other studies using smaller data
sets.26 27 Grandpaternal germline mosaicism
was found indirectly by haplotype analysis28 29
and by direct mutational analysis."8 Grandpa-
ternal somatic mosaicism was reported by
Lebo et al.30 Germinal mosaicism for a DMD
point mutation was first described by Wilton et
al.3' Kneppers et aP2 assumed that the recur-
rence risks for apparently new microlesions
were in the same range as for larger rearrange-
ments.
Bakker et alP0 found evidence of somatic
mosaicism in a female carrier passing the at risk
haplotype to a daughter who was not a carrier.
No evidence for chimerism or triple X, as was
postulated by Witkowski,33 was found in this
case. Somatic mosaicism in the mother of a son
with BMD and a carrier daughter was reported
by Voit et al.34 Bunyan et al3 reported somatic
mosaicism in a mother of a DMD patient using
FISH. RT-PCR and a polymorphism from the
area of the deletion were used to show somatic
mosaicism in another mother of a DMD
patient.36 Many somatic mosaics in whom the
cell lines with the mutation include a large
proportion of the lymphocytes are likely to
5 6 7
STR50
Figure 2 Microsatellite STR5O fails to amplify in the DMD patient (7) indicating a
deletion of exon 50. The mother (4) and sister (5) show loss of expected heterozygozity
which means they are carriers. The younger sister (6) is heterozygous and therefore not a
carrzer.
escape detection since the mother is usually
regarded as a carrier. This should skew the sex
ratio ofnew mutations towards a higher mater-
nal origin.24
Somatic mosaicism in a DMD patient was
reported by Uchino et al' using PCR fibre
analysis and by Saito et aP8 with immunocyto-
chemistry and PCR of different tissues.
FAMILY SITUATIONS
Occurrence of DMD or BMD patients and
carriers in a family can have different origins.
The various situations are considered here.
A woman with one affected son and no fam-
ily history of muscular dystrophy is either: (1) a
full carrier; (2) a somatic mosaic coinciding
with a partially (germline mosaicism) or totally
affected germline; (3) a germline mosaic; (4)
not a carrier, the ovum from which her son
arose contained a new mutation; (5) not a car-
rier, her diseased son is a somatic mosaic.
Depending on the proportion of muscle cells
that contain the mutation, a wide clinical spec-
trum can be expected.
Sisters of a boy apparently affected by a new
mutation are at risk of being a carrier because
the mother can be a germline mosaic. Subse-
quent brothers have the same risk of being
affected by the same mutation. This risk lies in
the order of 5-10%.20 24 We wish to stress that
the same risk applies to the sisters of a woman
who is apparently a carrier owing to a new
mutation.
A woman with more than one affected son
and no family history of muscular dystrophy
can be: (1) a full carrier; (2) a somatic mosaic
including her germline; (3) a germline mosaic.
If a woman has an affected son and also has
affected relatives in the maternal line, she is
regarded as a definite carrier. A woman with
one or more affected brothers but no affected
offspring is a possible carrier.
A woman can be a carrier because: (1) she
inherited the mutation from her mother who is
a carrier; (2) her mother or her father is a
somatic mosaic including the germline; (3) her
mother or her father is a germline mosaic; (4)
the ovum or sperm from which she arose con-
tained a new mutation; (5) she is a somatic
mosaic including her germline.
Methods ofmutation detection by DNA
analysis
DETECTION OF LARGE REARRANGEMENTS OF THE
DYSTROPHIN GENE
Polymerase chain reaction (PCR)
For PCR, only 100 ng DNA is necessary and
results can be obtained within one day. Select-
ed synthetic oligonucleotide primers amplify
specific sequences over a million-fold in vitro.
The two commonly used multiplex PCR kits
cover 18 exons in the deletion hot spots of the
dystrophin gene. They allow detection of 98%
of all deletions.39Al
In patients. Deleted exons cannot be ampli-
fied and are recognised as absent bands (fig 1).
Duplications might be detected under strictly
controlled quantitative conditions.
In carriers. Demonstration of heterozygosity
or hemizygosity ofpolymorphic markers within
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Figure 3 The cDNA blot hybridised with probe 63-3,4
shows a deletion of exon 53 (del) in the DMD patient (5)
and results in a junction fragment (J). Halfintensity of the
relevant band in the mother (2) indicates she is a carrier,
which is confirmed by the presence of the J band.
regions corresponding to the deletion in the
patient allows accurate deduction of carrier
status (fig 2) and is probably first choice for
carrier detection.42 Microsatellite markers are
very useful for this purpose. However, the
available markers are not informative in every
family. In uninformative families dosage analy-
sis of PCR products in female relatives can be
carried out using ethidium bromide staining,43
radioactive probes," or automated fluorescent
analysis.45 46 Stringent test conditions are
needed for reliable results. Competitive PCR
has recently been described as a method to
detect deletion heterozygotes. It involves a
comparison of the amplification efficiency of
the deleted area in carriers and controls and
has been shown to be successful in 80% of
families with deletion patients.47
Southern blotting
Southern blotting is more labour intensive than
PCR, usually takes several days, and requires a
minimum of 5 ,ug genomic DNA. Southern
blot analysis using dystrophin cDNA probes
has been described by Darras and Francke,48
Bakker et al,4 and Mao and Cremer.49
In patients. Deletions are recognised as
absent bands or band shifts (junction bands or
J bands) on the autoradiogram (figs 3 and 4). J
bands are found in less than 5% of patients.
Duplications appear as a double band intensity
in comparison to the normal situation or as
band shifts. Genomic probes (cosmids) can
also be used to detect J bands, which are found
in 81% of precisely mapped deletions.50 The
technically more demanding pulsed field gel
electrophoresis (PFGE) or field inversion elec-
trophoresis (FIGE)5' are methods to separate
long DNA fragments produced by rare cutting
enzymes and usually show J bands in deletions
larger than 20 kb. Alternatively, a newly devel-
oped Southern blotting based method uses rare
cutting restriction enzymes and electrophoresis
of single stranded DNA and detects J bands in
almost 80% of patients with deletions and
duplications.52
In carriers. Deletions or duplications which
produce a J band make carrier detection easy
and reliable (fig 3). As J bands are found in less
than 5% of the patients, carrier detection by
Southern blotting is mostly based on band
intensities. This requires quantitative blotting
conditions (fig 4). Depending on the practical
circumstances in the laboratory and the routine
of the personnel with quantitative blotting, this
method of carrier detection by dosage analysis
may have an increased chance of misdiagnosis,
especially when the patient cannot be
tested.3-
Reverse transcription PCR (RT-PCR)
Reverse transcription PCR (RT-PCR) trans-
forms mRNA to cDNA, which is then ampli-
fied. A fresh blood sample is needed for isolat-
ion and amplification of total RNA which
contains very low quantities of lymphocyte
dystrophin mRNA, resulting from illegitimate
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Figure 4 (A) Pedigree of the family. (B) The HindIII and BglII cDNA blots hybridised with probe 7b8 show a deletion
of exons 45-47 in the BMD patient (2). The mother (1), who is a carrier, shows half intensity of the relevant bands. The
sister (3) is not a carrier as she shows identical density for all bands compared with the normal control (C). (C) Graphical
representation of the in frame deletion in the patient.
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transcription (about one molecule per 500
cells)."
In patients. Deletions and duplications show
as abnormally sized products.57
In carriers. Heterozygotes are accurately de-
tected as they show two different sized products.
Fluorescent in situ hybridisation (FISH)
In patients. Fluorescent cosmid clones allow
microscopic detection of gross deletions as no
signal is detected. A control probe is needed to
avoid a conclusion based on false positive
results."4 58 59
In carriers. Carriers show one signal per
nucleus with cosmid probes from the region
corresponding with the deletion plus two con-
trol signals.
Immunological analysis of dystrophin in a muscle
biopsy
In patients. DMD patients usually lack detect-
able dystrophin on immunohistochemistry and
immunoblotting (<3%). BMD patients have
quantitative/qualitative dystrophin aberrations.
In carriers. Carriers may show mosaic
expression of dystrophin negative fibres.60 63
However, asymptomatic carriers are less likely
to give informative results. The study of differ-
entiating dystrophin positive and negative
clonal myoblasts in vitro may be another
approach,64 65 which has not gained popularity
yet. While it is hardly feasible as a routine
examination, it may be a last ditch method for
cases where no mutation is found and haplo-
typing is not informative. Forced myodifferen-
tiation in cultured fibroblasts is a recently
developed technique that may also help to find
carriers by dystrophin analysis or transcript
analysis in transformed clonal fibroblasts.66
From the above mentioned methods only
PCR, Southern blotting, and haplotyping are
routinely used in most diagnostic laboratories
nowadays.
METHODS FOR DETECTING MICROLESIONS IN THE
DYSTROPHIN GENE IN PATIENTS
Several methods are currently being used for
scanning for microlesions in genes,67 including
the dystrophin gene.'5 16 These methods are
described below. After a band shift has been
noted in the DNA of the patient, purified sam-
ples of aberrant PCR bands must be sequenced
for the identification of the mutation, as the
aberrant band might be caused by either a
polymorphism or a pathogenic mutation. Non-
sense mutations and frameshifts leading to a
stop codon, as well as splice site mutations, can
generally be considered pathogenic. For mis-
sense mutations the interpretation is more dif-
ficult. Criteria for pathogenicity are absence of
the mutation in controls, a change of polarity
or size of the amino acid in the encoded
protein, occurrence of the amino acid change
in a conserved domain, or detrimental effect of
the mutation in a functional in vitro system or
in an animal model.
2
Figure 5 SSCP analysis shows a band shift in the DMD
patient (2). Sequencing showed a stop mutation at position
1697 in exon 12. The mother (1) carries the same
mutation, while the grandmother (4) is not a carrier.
Single strand conformation polymorphism
(SSCP)
SSCP has the potential to detect all small
mutations. A mutation in the single DNA
strand causes altered folding and thus altered
migration during electrophoresis. In practice,
35-100% of known mutations can be detected
as an aberrant band pattern by SSCP and its
modifications.66 69 Application of various differ-
ent electrophoretic conditions increases the
chance of finding an aberrant band caused by
the mutation (fig 5). SSCP of exons of the
deletion prone regions leads to the detection of
pathogenic mutations in about 10% of
cases.32 70 71 SSCP is rarely used for detection of
large rearrangements.72
Heteroduplex analysis (HDA)
In HDA, after denaturation of the amplified
fragments, rehybridisation of the single strand-
ed patient DNA and control DNA produces
four hybridisation products, one hybrid with
two normal strands, one with two abnormal
strands, and two with a normal and a mutated
strand. These products migrate differently
during electrophoresis. Applications to dys-
trophin gene mutation screening are described
by Prior et al73 and Barbieri et al.74
Protein truncation test (PTT)
The PTT screens DMD lymphocyte mRNA
for translation terminating mutations by RT-
PCR and subsequent in vitro translation/
transcription." 7 7 Truncated dystrophin pro-
ducts are seen in patients with stop mutations
(fig 6). Owing to its selectivity for truncating
Figure 6 PTT shows part of truncated dystrophin protein
after electrophoresis in the DMD patient (P) and not in the
normal control (C).
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mutations, the PTT is not useful for mutation
detection in most BMD patients in whom stop
mutations are rare.
Chemical mismatch cleavage (CMC)
CMC detects single base mismatches contain-
ing cytosine or thymidine in heteroduplexes
from patient DNA and control DNA. The mis-
matched bases are chemically modified and
thereby create a cleavage site. Applications to
dystrophin mutation screening have been de-
scribed by Roberts et all' and Kilimann et al.8"'
Denaturing gradient gel electrophoresis (DGGE)
DGGE separates DNA fragments with a CG
clamp by their different melting behaviour in a
denaturing gradient. DGGE has a very high
mutation detection rate8 82 and has recently
been used for mutation analysis of muscle and
brain specific promoter regions of the dys-
trophin gene.83
MICROLESION DETECTION IN CARRIERS
Once the mutation has been found in the
patient, reliable carrier detection is possible by
sequencing only a short section of the dys-
trophin gene. Alternatively, when the mutation
produces or abolishes a restriction site, this also
enables carrier detection for that mutation. In
the absence of patient material, close female
relatives may be tested directly for aberrant
bands. The PTT can also be used for DMD
carrier detection when no patient material is
available.
Procedure for genetic analysis
Depending on the availability of the patient
and the presence of a detectable mutation in
DNA of the patient the following approaches
are suggested.
PATIENT DNA AVAILABLE, MUTATION DETECTABLE
BY PCR/SOUTHERN BLOTTING
When a deletion or duplication is detected in
the patient, quantitative Southern blotting
allows for dosage analysis in female relatives
with at least two digests with different restric-
tion enzymes (for example, BglII, HindIII,
PvuII) to confirm the presence and extent of
the deletion or duplication and to detect carri-
ers. When the deletion or duplication produces
a J band, carrier detection is straightforward.
However, most deletion carriers are detected
by a decreased intensity of the band correspon-
ding to the deletion in the affected male
relatives. In patients, duplications increase
band intensity by a 2:1 ratio. Duplication carri-
ers, however, are more difficult to detect as
band intensity is only increased by a 3:2 ratio.
Interpretation of quantitative blots requires
independent examination by at least two quali-
fied persons.
Carrier detection by differences in band
intensities should preferably be confirmed
using informative polymorphisms in the region
corresponding to the deletion. This means that
DNA of the parents of the carrier should also
be available. Short tandem repeat (STR)
markers are very useful for this purpose.1i
Alternatively, another qualitative carrier test
can be used, such as PFGE, RT-PCR, or FISH.
PATIENT DNA AVAILABLE, MUTATION NOT
DETECTABLE WITH PCR OR SOUTHERN BLOTTING
When no dystrophin gene mutation can be
detected, immunoblotting in a muscle biopsy
from the patient is important to confirm DMD.
Immunohistochemistry may differentiate
between DMD and BMD. Testing for defi-
ciency of proteins from the transmembrane
sarcoglycan complex is indicated in dystrophin
positive myopathies84 87 to identify autosomal
recessive limb-girdle muscular dystrophy. Mu-
tations in the genes for the sarcoglycan proteins
occur in about 10% of patients with DMD-like
and limb-girdle dystrophy with normal
dystrophin.8
In DMD or BMD diagnosed with certainty,
SSCP, HDA, PTT, or another test for mutation
scanning should be tried to screen the
dystrophin gene for a mutation whenever pos-
sible. When an aberrant band is found, that
band must be amplified and sequenced for a
pathogenic mutation. Carrier detection will
then also be possible by sequencing this region.
When the mutation produces or abolishes a re-
striction site, restriction analysis can be used as
a ready confirmation of carrier status.
In families where the mutation cannot be
detected, carrier risks have to be based on the
pedigree, serum CK activities in close female
relatives, and linkage data using flanking and
intragenic markers. In these cases automated
calculation programs can be helpful. However,
possible recombinations remain a drawback in
linkage analysis. The very high intragenic
recombination of 12% across the dystrophin
gene43 88 demands combined use of flanking
and intragenic markers. Highly informative
polymorphisms are the first choice. In the case
of inconsistent results in linkage analysis, sam-
pling errors and non-paternity should be borne
in mind. About 2/3 of DMD carriers have
raised serum CK activities.88 These are also
found in about 1/2 ofBMD carriers.80 It should
be taken into account that raised serum CK
activities occur in about 1 in 20 females in the
population and that during pregnancy serum
CK activities tend to decline.' 92
PATIENT DNA NOT AVAILABLE
In families where patient DNA is not available,
a search for stored muscle biopsy, Guthrie
spots,93 or deciduous teeth84 may be worth-
while. When none of these sources of DNA is
available, band intensity can be determined in
quantitative PCR blots or Southern blots or
both in female relatives. Detection ofJ bands in
Southern blots would, of course, be most help-
ful. If unsuccessful, PFGE, RT-PCR, SSCP,
FISH, and PTT can be considered.
Risk calculation
Risk calculation is needed in families where the
mutation cannot be detected. Determination of
carrier risks may be difficult, particularly in
isolated cases. By including serum CK activi-
ties in female relatives as well as pedigree and
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haplotype information in a Baysian calculation,
carrier risks may be estimated. As already
mentioned, the huge dystrophin gene has an
estimated recombination across the gene se-
quence of 12%.88 95
Risk calculations usually assume an equal
mutation rate in spermatocytes and oocytes.96
However, Grimm et al97 suggest that most point
mutations arise during spermatogenesis. If so,
this would raise the a priori carrier risk of the
mother from 67% to at least 76%. Another
complicating factor in risk calculations is the
presence of germline or somatic mosaicism.
Approaches to risk calculation have been
described in a few reports, to which the reader
is referred.9..'°'
Genetic counselling
Ideally, both partners should be counselled
before laboratory tests are considered. All
available options in their situation should be
discussed with them, including prenatal diag-
nosis and preimplantation diagnosis, with their
limitations and potential complications, such
as risk of abortion and recombination between
markers in the child causing uninformative test
results.
Prenatal diagnosis
Chorionic villus biopsy is preferred by most
couples opting for prenatal diagnosis. Usually
PCR will be used in prenatal diagnosis of male
fetuses. PCR results are generally not influ-
enced by low levels (<5%) of maternal
contamination. However, in the case of a male
fetus in which no mutation is detected,
informative polymorphisms in the mother
should be used to exclude maternal contami-
nation.
Fetal muscle biopsy in male fetuses at risk
may be considered in a situation where linkage
analysis is uninformative or recombination has
occurred,10115 but has an approximately 5%
risk of fetal loss. As an alternative, immu-
nological analysis of dystrophin expression
after induction of myogenesis in fetal fibro-
blasts, amniocytes, or chorionic villus cells can
be considered.'06 Additionally, RT-PCR of dys-
trophin mRNA isolated from these transform-
ed cells might help to identify the mutation.66
Clinical application of non-invasive prenatal
DNA diagnosis of fetal cells in maternal blood
is being studied.'07 This type of approach, how-
ever, still faces major general problems.'08
Preimplantation diagnosis (PID)
In PID one or two cells are removed from the
6-8 cell pre-embryos three days after concep-
tion. In a nested PCR, the target exons of these
cells are amplified for sex determination or
mutation detection. Important drawbacks of
PID are that in 20% of cases single cell PCR
fails to produce sufficient DNA for analysis and
that the chance of establishing a pregnancy
when two or three pre-embryos are replaced is
about 15-20% for each procedure. Since PID
should still be considered as an experimental
method,'09 110 couples using PID are offered
verification of the diagnosis by prenatal dia-
gnosis. Liu et al"'. analysed exon 17 in four
embryos at risk for a deletion of exons 3-18 and
three were found to be normal and were
replaced. A singleton pregnancy was the even-
tual result.
Discussion
Although the possibilities for detecting micro-
lesions in the dystrophin gene are increasing,
still for the near future in about 30% of families
mutation detection will not be in the standard
package of most diagnostic laboratories. Fortu-
nately, linkage analysis and determination of
serum CK activities in female relatives mostly
enable a fairly accurate determination of
carrier risks in these families. This may even be
possible when no DNA from the patient is
available. However, families with patients who
have already died might pose serious problems
in assigning carriers risks, although the PTT
and other approaches might directly detect
female carriers. Therefore, every physician
involved with muscular dystrophy patients
should obtain and store cells from DMD and
BMD patients for DNA and RNA extraction or
for establishing a cell line or both.
In practice, DGGE may detect more muta-
tions than SSCP. Therefore, further develop-
ment of DGGE will be worthwhile. In a two
dimensional DNA electrophoresis method,
DGGE preceded by extensive PCR multiplex-
ing has recently been proven to be very effective
in detecting mutations in the 200 kb sized RB 1
gene with its 27 exons."12 The ideal setting for
the future is a quick reliable mutation scanning
system for the whole dystrophin gene. Two
dimensional DNA electrophoresis"2 "II might
have this potential and needs to be evaluated
further.
At present prenatal diagnosis by chorion vil-
lus sampling will be the only realistic option for
many DMD and BMD carriers who want to
have children of their own. PID needs to be
optimalised in order to become a more accept-
able option for many parents. In polar body
biopsy the at risk haplotype or mutation in the
polar body implies presence of the normal
allele in the primary oocyte, but this method
has not been used in diagnosis of DMD or
BMD.
As the majority of DMD and BMD cases
cannot be prevented, hopefully gene therGpy
will provide young DMD and BMD patients
with a way of stopping disease progression.
However, there are still major obstacles to be
overcome."15 116
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